GOLPH3 and ductal breast carcinoma in situ: In the 339 DCIS cases without recurrence, the percentages of grades 3 (high), 2 (low), and 1 of GOLPH3 immunostaining were 6.78% (23/339), 4.13% (14/339), and 89.09% (302/339), respectively.